Table 1.
Phase II/III trials with anti vascular-endothelial growth factor agents for advanced gastric cancer and gastro-esophageal junction cancers
| Trial | Phase | Setting | Regimen | Patients (n) | RR | OS (mo) | TTP/PFS (mo) |
| NCT00084604[49], 2006 | II | 1st line | Iri + C + Bev | 47 | 65% | 12.3 | 8.3 |
| NCT00217581[50], 2010 | II | 1st line | DOCOX + Bev | 38 | 59% | 11.1 | 6.61 |
| AVAGAST[51,54], 2010 | III | 1st line | XC + Bev | 387 | 46% | 12.1 | 6.7 |
| XC + Placebo | 387 | 37.4% | 10.1 | 5.3 | |||
| ST03[55], 2012 | II/III | Perioperative | ECX-B | 200 | - | - | - |
| REGARD[58], 2012 | III | 2nd line | Ram + BSC | 235 | - | 5.2 | 2.11 |
| BSC | 117 | 3.8 | 1.71 | ||||
| RAINBOW[60], 2014 | III | 2nd line | PTX + Ram | 665 | 28% | 9.6 | 4.4 |
| PTX + placebo | |||||||
| ECOG 5203[63], 2010 | II | 1st line | TXT + C + Sor | 44 | 39% | 13.6 | 5.8 |
| NCT01262482[64], 2012 | II | 2nd line | Sor + O | 40 | - | 6.5 | 3.01 |
| NCT00411151[67], 2011 | II | 2nd line | Sun | 52 | 3.9% | 5.81 | 1.281 |
| NCT00226811[68], 2011 | II | 2nd line | Sun | 78 | 2.6% | 6.8 | 2.3 |
| NCT00970138[73], 2011 | II | 3rd line | A: Placebo | - | 2.5 | 1.41 | |
| B: Apa (850 mg) | - | 4.83 | 3.671 | ||||
| C: Apa (425 mg bid) | 144 | 4.27 | 3.21 | ||||
| NCT01512745[74], 2012 | III | 3rd line | Apa | - | - | - | - |
| Placebo | |||||||
| TEL0805 trial[75], 2011 | II | 1st line | XC + Tel | 39 | 6.7% | - | - |
1
Progression free survival (PFS). Iri: Irinotecan; Cis: Cisplatin; Bev: Bevacizumab; X: Capecitabine; C: Cisplatin; E: Epirubicin; Ram: Ramucirumab; PTX: Paclitaxel; Sor: Sorafenib; Sun: Sunitinib; Apa: Apatinib; Tel: Telantinib; DOCOX: Docetaxel plus oxaliplatin; O: Oxaliplatin; TXT: Docetaxel; BSC: Best supportive care; RR: Response rate; OS: Overall survival; TTP/PFS: Time to progression/progression free survival.